Literature DB >> 11737083

Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters.

M R Jacobs1.   

Abstract

To understand the relationship between drug dose and efficacy, pharmacokinetic (PK) and pharmacodynamic (PD) characteristics need to be integrated. Patterns of antimicrobial activity fall into one of two major patterns: time-dependent killing and concentration-dependent killing. Time-dependent killing is characteristic of many antibiotic classes, such as beta-lactams and macrolides, and seeks to optimise the duration of exposure of a pathogen to an antimicrobial. The major PK/PD parameter correlating with efficacy of time-dependent antimicrobials is the serum concentration present for 40-50% of the dosing interval, and this concentration is the susceptibility limit or breakpoint for the dosing regimen used. The second pattern, concentration-dependent killing, seeks to maximise antimicrobial concentration and is seen with aminoglycosides, quinolones and azalides. The major PK/PD parameter correlating with efficacy of these agents is the 24-h area under the curve to MIC ratio, which should be > or =25 for less severe infections or in immunocompetent hosts, and > or =100 in more severe infections or in immunocompromised hosts. PK/PD breakpoints for concentration-dependent agents can therefore be calculated from the formula AUC divided by 25. This enables development of PK/PD breakpoints based on the above parameters for time- and concentration-dependent agents for defined dosing regimens. For an antimicrobial to be useful empirically, the MIC90s of the agent against the common pathogens responsible for the disease being treated should be below the PK/PD breakpoint. This is particularly important for oral dosing regimens for treating emerging resistant respiratory tract pathogens, where efficacy against the predominant pathogens, Streptococcus pneumoniae and Haemophilus influenzae, is required.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11737083     DOI: 10.1046/j.1198-743x.2001.00295.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  65 in total

Review 1.  Bacteraemic pneumococcal pneumonia: current therapeutic options.

Authors:  Charles Feldman; Ronald Anderson
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

2.  Population Pharmacokinetics and Dosing Optimization of Amoxicillin in Neonates and Young Infants.

Authors:  Bo-Hao Tang; Yue-E Wu; Chen Kou; Yu-Jie Qi; Hui Qi; Hai-Yan Xu; Stephanie Leroux; Xin Huang; Yue Zhou; Yi Zheng; Evelyne Jacqz-Aigrain; A-Dong Shen; Wei Zhao
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

3.  Effects of various media on the activity of NXL103 (formerly XRP 2868), a new oral streptogramin, against Haemophilus influenzae.

Authors:  Glenn A Pankuch; Dianne Hoellman; André Bryskier; John Lowther; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2006-11       Impact factor: 5.191

4.  Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis.

Authors:  Tatiana Bogdanovich; Catherine Clark; Lois Ednie; Gengrong Lin; Kathy Smith; Stuart Shapiro; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

5.  The treatment of acute bacterial sinusitis: no change is good medicine.

Authors:  Nicole Le Saux
Journal:  CMAJ       Date:  2008-03-25       Impact factor: 8.262

6.  Activity of LBM415 compared to those of 11 other agents against Haemophilus species.

Authors:  Tatiana Bogdanovich; Kathy A Smith; Catherine Clark; Glenn A Pankuch; Gengrong Lin; Pamela McGhee; Bonifacio Dewasse; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

7.  A Population and Developmental Pharmacokinetic Analysis To Evaluate and Optimize Cefotaxime Dosing Regimen in Neonates and Young Infants.

Authors:  Stéphanie Leroux; Jean-Michel Roué; Jean-Bernard Gouyon; Valérie Biran; Hao Zheng; Wei Zhao; Evelyne Jacqz-Aigrain
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

Review 8.  Pharmacokinetics and pharmacodynamics of antibacterial agents.

Authors:  Matthew E Levison; Julie H Levison
Journal:  Infect Dis Clin North Am       Date:  2009-12       Impact factor: 5.982

9.  In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.

Authors:  Jeffrey Fernandez; Jamese J Hilliard; Darren Abbanat; Wenyan Zhang; John L Melton; Colleen M Santoro; Robert K Flamm; Karen Bush
Journal:  Antimicrob Agents Chemother       Date:  2009-11-02       Impact factor: 5.191

10.  Antimicrobial breakpoint estimation accounting for variability in pharmacokinetics.

Authors:  Goue Denis Gohore Bi; Jun Li; Fahima Nekka
Journal:  Theor Biol Med Model       Date:  2009-06-26       Impact factor: 2.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.